Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Hematologic Malignancies I

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
 
7500 Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
 
Curtis Andrew Lachowiez, Gautam Borthakur, Sanam Loghavi, et al.
 
The abstract concludes: 
IVO+VEN +AZA therapy is well tolerated and highly effective for patients with IDH1 mutated AML. Follow up and accrual is ongoing to better define duration and biomarkers of response. Clinical trial information: NCT03471260
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————
7501 Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
 
Courtney Denton Dinardo, Andre C. Schuh, Eytan M. Stein, et al.
 
The abstract concludes: 
Combining ENA + AZA resulted in significantly improved response rates and durations, and was generally well-tolerated in older patients with mIDH2 ND-AML. The impact of subsequent Tx on OS/EFS and new translational data will be presented at the meeting. Clinical trial information: NCT02677922.
————————————————————————————————————————————————————————
 
7502 Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.
 
Jorge E. Cortes, Elza Lomaia, Anna Turkina, et al.
 
The abstract concludes: 
OPTIC IA shows a trend toward dose-dependent efficacy and safety and may provide a refined understanding of the PON benefit:risk profile and its relation to dose. Data from longer follow-up may support an alternate dosing regimen for pts with CP-CML.
————————————————————————————————————————————————————————
 
7503 Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.
 
Muna Qayed, Carrie L Kitko, Kwang Woo Ahn, et al.
 
The abstract concludes: 
This validated p-DRI successfully stratified children with AML and ALL for prognostication undergoing allogeneic transplantation.
————————————————————————————————————————————————————————
 
7505 Post-traumatic stress symptoms in hematopoietic stem cell transplant (HCT) recipients.
 
Sarah Griffith, Alyssa L. Fenech, Ashley Nelson, et al.
 
The abstract concludes: 
Approximately one fifth of patients undergoing HCT experienced clinically significant PTSD symptoms at six months post-transplant. Patients’ baseline QOL and psychological symptoms emerged as important predictors of their risk for PTSD at six months post-HCT. Thus, interventions to prevent and treat PTSD symptoms in HCT recipients are clearly warranted.
————————————————————————————————————————————————————————
 
7506 Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
 
Lionel Ades, Justin M. Watts, Atanas Radinoff, et al.
 
The abstract concludes: 
P+A had a comparable safety profile to A alone, did not increase myelosuppression, and maintained A dose intensity. Although not statistically significant, P+A increased OS, EFS, and response rates vs A, particularly in pts with higher-risk MDS. Further evaluation of P+A vs A is ongoing in a randomized phase. Clinical trial information: NCT02610777.
————————————————————————————————————————————————————————
 
7507 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
 
David Andrew Sallman, Monzr Al Malki, Adam Steven Asch, et al.
 
The abstract concludes: 
Magrolimab is a macrophage targeting immunotherapy that with AZA is well tolerated with durable efficacy in MDS, AML, particularly TP53 mutant, a poor prognostic group. A potential registration single arm MDS cohort is ongoing (NCT03248479). ENHANCE, a randomized Ph3 MDS trial is planned. Additional patients/analyses will be reported. Funded by Forty Seven and CIRM. Clinical trial information: NCT03248479.
 
————————————————————————————————————————————————————————
 
7508 Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
 
Farhad Ravandi, Roland B. Walter, Marion Subklewe, et al.
 
The abstract concludes: 
AMG 330 dosed up to 720 μg/day provided early evidence of acceptable safety profile, drug tolerability and anti-leukemic activity, and supports further dose escalation. Clinical trial information: NCT02520427.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
view slide set
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
 
Poster Session
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Hematologic Malignancies (Abstracts #7500, 7501, 7508)
Access Content Now